SenoRx Announces Claim Construction Hearing Held in Pending Hologic V. SenoRx Litigation
ALISO VIEJO, Calif., Oct. 16, 2008 (GLOBE NEWSWIRE) — SenoRx (Nasdaq:SENO) today announced that a Markman claim construction hearing was held on October 15, 2008 by the United States District Court for the Northern District of California in the currently pending patent litigation between Hologic and SenoRx. No ruling has yet been issued.
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx’s field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distributors in more than 20 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company’s website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: SenoRx, Inc. Lila Churney, Director of Investor Relations 949-362-4800 x132